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Abstract: The efficacy and safety of the dipeptidyl peptidase-4 inhibitor, vildagliptin, as 
monotherapy have been widely confirmed in a large body of clinical studies of up to 2 years’ 
duration in various populations with type 2 diabetes mellitus. This paper reviews the data 
supporting the use of vildagliptin in monotherapy. Consideration based on baseline glycated 
hemoglobin levels and age is given to patient segments where metformin is not appropriate. In 
addition, although prediabetes is not an indication, this manuscript briefly reviews some of the 
existing data showing that the mechanisms at work in diabetic populations are active in patients 
currently classified as prediabetic, with impaired glucose tolerance or impaired fasting glucose. 
Finally, the rationale for vildagliptin dosing frequency in monotherapy is discussed. In summary, 
this review aims to define where in community practice the use of vildagliptin as monotherapy is 
most desirable, focusing on segments of the population with type 2 diabetes mellitus that might 
receive the greatest benefit from vildagliptin in the management of their disease.
Keywords: vildagliptin, type 2 diabetes, dipeptidyl peptidase-4 inhibitors, monotherapy, 
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Introduction
Vildagliptin is a potent and selective dipeptidyl peptidase-4 inhibitor (DPP-4) that blocks 
dipeptidyl peptidase-4 inactivation of glucagon-like peptide-1 (GLP-1) and glucose-
dependent insulinotropic polypeptide (GIP).1 Vildagliptin has been extensively studied 
in multiple clinical studies, including various populations with type 2 diabetes mellitus 
(T2DM).2 The drug has demonstrated efficacy when given as monotherapy or in combina-
tion with other antidiabetic drugs or insulin.2–4 Vildagliptin is well tolerated and has a low 
risk of hypoglycemia and weight gain. Its efficacy when added to metformin5 as well as 
its safety (overall6 but also with respect to cardiovascular and cerebrovascular events7 and 
adverse events of special interest8) has been thoroughly reviewed elsewhere, including 
in special populations such as the elderly.9,10 Several recent reviews have also focused on 
a number of the drug’s additional key features, including its mechanism of action,11 its 
weight neutrality,12 and its benefit in terms of hypoglycemia.13 Additionally, the overall 
efficacy and safety of vildagliptin were assessed in a recent meta-analysis.14
Numerous clinical studies of vildagliptin monotherapy have been published, 
although these papers do not provide any guidance as to how vildagliptin might be used 
as monotherapy in clinical practice. Therefore, we deemed it important to try to define 
how the drug might be used most effectively in monotherapy, ie, which segments of 
the diabetic population would benefit most from vildagliptin monotherapy.
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Currently, most T2DM patients begin and then continue 
gold standard treatment of metformin.15 However, a small 
percentage of patients cannot tolerate metformin due to 
gastrointestinal side effects, such as diarrhea and nausea,16 
and metformin is contraindicated for individuals with 
congestive heart failure, renal disease, or acute or chronic 
acidosis. For example, in a recent US cohort from Kai-
ser Permanente, 17% of patients who started metformin 
monotherapy discontinued before 6 months.17 In some 
countries (predominantly in Asia), the alpha-glucosidase 
inhibitors (eg, acarbose, migital) are frequently used instead 
of metformin as first-line therapies. The use of alpha-
glucosidase inhibitors is limited by its dosing requirements 
(taken three times daily before meals), by its gastrointestinal 
symptoms (arising from fermentation of undigested carbo-
hydrates by colonic bacteria), and by the fact that both its 
efficacy and its gastrointestinal side effects are influenced 
by diet (with an advantage when rice is the major source of 
carbohydrate in the diet).18
Alternatives for patients who cannot take metformin 
include the thiazolidinediones and the sulfonylureas. 
  However, the use of thiazolidinediones is quite limited at 
present. Even pioglitazone (the only available glitazone in 
Europe) might not remain a common alternative over the 
years to come because of uncertainties about its safety, given 
that long-term use has been associated with elevated rates 
of bone fracture19 and bladder cancer.20,21 In most countries, 
the most common first-line alternatives to metformin are the 
sulfonylureas, eg, gliclazide, glimepiride, glibenclamide, 
and glipizide. The major limitations of sulfonylureas are 
an increased risk of hypoglycemia and weight gain.22 These 
limitations are most evident when sulfonylureas are used 
in patients with lower baseline glycosylated hemoglobin 
(HbA1c) levels (in particular #8%),23 and in elderly patients, 
who are at risk of more frequent and severe hypoglycemia and 
for whom the potential consequences of hypoglycemia are 
more dangerous.24 Thus, for those individuals, sulfonylureas 
may not be optimal first-line therapy and vildagliptin could 
represent an interesting option.
This paper examines the data for vildagliptin in these 
particular segments of the T2DM population. In addition, 
although prediabetes is currently not an accepted indication 
in most countries (except, eg, voglibose in Japan or acarbose 
in China), this paper will also review the data with vildagliptin 
in individuals classified as having prediabetes with impaired 
glucose tolerance or impaired fasting glucose in whom the 
mechanisms are already operative.11 An overview of all stud-
ies discussed in this paper is presented in Table 1.
Overview and patients with mild 
hyperglycemia
We will first briefly review the main data in the broad 
monotherapy population and then focus on the patient 
segments of particular interest. The overall efficacy of 
vildagliptin in monotherapy has been well demonstrated in 
several pivotal studies.25–34 All these studies were conducted in 
drug-naive patients with T2DM independent of intolerance or 
contraindications to metformin. These monotherapy studies 
provide evidence that treatment with vildagliptin results in 
consistent and clinically meaningful reductions from baseline 
in HbA1c of approximately −1%, without weight gain and 
with minimal hypoglycemia.
In an early trial, conducted in 780 patients randomized 
to vildagliptin 50 mg twice daily or metformin 2 g daily, 
robust HbA1c reductions from a baseline of 8.7% were 
attained at one year with both vildagliptin (−1.0%) and 
metformin (−1.4%), although vildagliptin was not nonin-
ferior to metformin.32 Twice as many patients experienced 
gastrointestinal adverse events in the metformin group, 
driven by a 3–4-fold greater incidence of diarrhea, nausea, 
and abdominal pain. Efficacy was equally well sustained 
with both treatments over 2 years in the extension study, 
with a mean HbA1c reduction of −1.0% with vildagliptin 
from a baseline of 8.4% and a continued benefit in terms of 
gastrointestinal tolerability.27,32
Clinically relevant efficacy of vildagliptin was also seen 
in a 24-week study comparing vildagliptin (50 mg twice daily, 
n = 519) and rosiglitazone (8 mg daily, n = 267). Both drugs 
decreased HbA1c to a similar extent over 24 weeks (statistical 
noninferiority established), with improvements in HbA1c of 
−1.1% with vildagliptin and −1.3% with rosiglitazone from 
a baseline of 8.7%, and showing some weight benefit with 
vildaglitpin (−1.9 kg relative to rosiglitazone).29
In a study conducted with vildagliptin 50 mg twice daily 
versus a sulfonylurea (gliclazide up to 320 mg/day) over a 
2-year period, the reductions in HbA1c were similar with both 
drugs (−0.5% and −0.6%, respectively), although noninferior-
ity to gliclazide was narrowly not established, and vildagliptin 
had modest benefits in terms of weight and hypoglycemia.26 
It is important to point out that with the high baseline HbA1c 
seen in this study (8.7% in the gliclazide group and 8.5% 
in the vildagliptin group), any benefit on hypoglycemia and 
weight versus a sulfonylurea would be expected to be limited, 
while these benefits would be considerably more pronounced 
with a lower baseline HbA1c level, as was indeed demon-
strated in a study comparing vildagliptin with sulfonylurea 
as an add on to metformin therapy.4,35
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Table 1 Vildagliptin monotherapy studies
Study Study description Randomized patients* Treatment duration** Reference
1 Placebo-controlled dose-ranging study  
(efficacy/safety) in drug-naïve T2DM  
patients (HbA1c 7.5%–10.0%)
354 24 weeks 34
2 Placebo-controlled dose-ranging study  
(efficacy/safety) in drug-naïve T2DM  
patients (HbA1c 7.5%–10.0%)
632 24 weeks 25
3 Placebo-controlled long-term efficacy/safety study in  
drug-naïve T2DM patients with mild hyperglycemia  
(HbA1c 6.2%–7.5%)
306 52 weeks 31
4 Placebo-controlled 52-week extension to study 3 131 104 weeks 30
5 Placebo-controlled mechanistic study in  
drug-naïve T2DM patients with mild  
hyperglycemia (HbA1c # 7.5%)
89 52 weeks 36
6 Placebo-controlled efficacy/mechanistic  
study in diet-controlled T2DM patients  
(HbA1c 6.3%–10.0%)
40 4 weeks 38
7 Placebo-controlled mechanistic study in  
drug-naïve T2DM patients (HbA1c 6.5%–10.0%)
31 4 weeks 39
8 Placebo-controlled mechanistic study in  
drug-naïve T2DM patients (HbA1c # 7.5%)
30 4 weeks 40
9 Active-controlled (metformin) long-term  
efficacy/safety study in drug-naïve  
T2DM patients (HbA1c 7.5%–11.0%)
780 52 weeks 32
10 Active-controlled (metformin) 52-week  
extension to study 9
463 104 weeks 27
11 Active-controlled (metformin) efficacy/safety study  
in drug-naïve elderly ($65 years) T2DM patients  
(HbA1c 7.0%–9.0%)
335 24 weeks 33
12 Active-controlled (gliclazide) long-term efficacy/safety 
study in drug-naïve T2DM patients (HbA1c 7.5%–11%)
1092 104 weeks 26
13 Active-controlled (acarbose) efficacy/safety study in  
drug-naïve T2DM patients (HbA1c 7.5%–11%)
661 24 weeks 28
14 Active-controlled (rosiglitazone) efficacy/safety study  
in drug-naïve T2DM patients (HbA1c 7.5%–11%)
786 24 weeks 29
15 Active-controlled (voglibose) efficacy/safety study in  
Japanese T2DM patients (HbA1c 6.5%–10%)
380 12 weeks 37
16 Placebo-controlled study in subjects with iGT 179 12 weeks 49
17 Uncontrolled study in subjects with iFG 22 6 weeks 50
18 Pooled monotherapy analysis in patients  
, and $65 years
NA $24 weeks 10
19 Pooled monotherapy analysis in patients  
, and $75 years
NA $24 weeks 45
Notes: *For extension studies, patients who entered extension; **For extension studies, duration of core + extension study.
Abbreviations: HbA1c, glycosylated hemoglobin; iGT, impaired glucose tolerance; iFG, impaired fasting glucose; NA, not applicable; T2DM, type 2 diabetes.
The efficacy of vildagliptin monotherapy was also 
established in an Asian population. In a 24-week mono-
therapy study, vildagliptin 50 mg twice daily showed efficacy 
comparable with that of acarbose administered up to 100 mg 
three times daily in Chinese patients (−1.4% versus −1.3% 
from a baseline of 8.6%; statistical noninferiority established) 
and was associated with significantly better gastrointestinal 
tolerability than was the alpha-glucosidase inhibitor.28
In a placebo-controlled 24-week study, HbA1c was signifi-
cantly reduced versus placebo by −0.48%, −0.73%, and −0.85% 
with vildagliptin 50 mg once daily, 50 mg twice daily, and 
100 mg once daily, respectively, from baselines of 8.3%–8.4%, 
with no weight gain and no hypoglycemia.25,34 Statistically 
significant reductions versus placebo were also seen with 
vildagliptin in a second study of identical design, although in 
this study similar reductions in HbA1c were seen with 50 mg 
and 100 mg daily,25,34 as discussed further below.
In trying to define how vildagliptin might be used most 
effectively in monotherapy, the first patient segment of 
interest is patients with relatively mild hyperglycemia. As 
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outlined above, for patients in whom the dose or use of 
metformin is limited (mostly because of gastrointestinal and 
glomerular filtration rate limitations), using a sulfonylurea as 
alternative monotherapy treatment is less desirable in patients 
at low baseline HbA1c because of the increased likelihood of 
hypoglycemia,23 which creates a greater need for other drug 
choices in this patient group.
The benefit of vildagliptin monotherapy in patients with 
mild hyperglycemia was evaluated in a series of studies that 
showed the positive effects of treatment with   vildagliptin 
on glucose control and β-cell function in this patient 
population.30,31,36
In a one-year, placebo-controlled study involving 306 
drug-naive T2DM patients with a mean HbA1c of 6.7%, those 
randomized to vildagliptin 50 mg once daily plus lifestyle 
counseling showed a significant reduction in HbA1c (−0.3%), 
fasting plasma glucose (−0.4 mmol/L), and postprandial 
glucose (−0.9 mmol/L) after 52 weeks, relative to those 
receiving placebo plus lifestyle counseling (Figure 1).31 
A one-year extension was conducted (total study duration 
2 years) and showed continued improvement with vilda-
gliptin relative to placebo, with a placebo-adjusted change 
in HbA1c of −0.5% from core study baseline after 2 years. 
Body weight decreased significantly in vildagliptin-treated 
patients (−1.1 kg versus −0.3 kg with placebo), and two 
placebo-treated patients (3.2%) versus none (0.0%)   receiving 
vildagliptin experienced hypoglycemia over 2 years. Taken 
together, 104 weeks of treatment with vildagliptin in this 
study mitigated the progressive loss of glycemic control 
observed in patients with mild hyperglycemia receiving 
placebo and lifestyle counseling without exposing them to 
hypoglycemia or weight gain.30 This appears to be because 
of a corresponding attenuation of the deterioration of β-cell 
function as assessed by the insulin secretion rate relative to 
glucose over one and 2 years.30 β-cell function also showed 
significant improvement with vildagliptin 100 mg once daily 
in a subsequent study in the same patient population, which 
demonstrated that vildagliptin significantly increased the 
insulin secretory capacity of β-cells, using the current gold 
standard clamp assessment of β-cell secretory capacity.36
Another monotherapy study (24 weeks) with vildagliptin 
in a low baseline population (mean HbA1c 7.7%) was con-
ducted versus metformin 1.5 g daily in patients aged 65 years 
and older. This study showed that vildagliptin 100 mg once 
daily was as effective as metformin in this population, 
improving HbA1c by −0.64% and −0.75%, respectively 
(noninferiority established), with fewer gastrointestinal 
adverse events with vildagliptin (15.0% versus 24.8% with 
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Figure 1 Time course of mean HbA1c during one year of treatment with vildagliptin 50 mg once daily (closed triangles) or placebo (open circles).
Notes: Vildagliptin: n = 153 at baseline and 138 at week 52; placebo: n = 149 at baseline and 131 at week 52. Mean ± standard error. ***P , 0.0001 versus placebo.
Adapted with permission from Scherbaum et al.31
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metformin, P = 0.028), mainly driven by a 4.4-fold higher 
incidence of diarrhea with metformin.33
The efficacy of vildagliptin monotherapy in patients with 
low baseline HbA1c was also evaluated in an Asian   population. 
In a 12-week study in Japanese patients, vildagliptin reduced 
HbA1c by −0.95% from a baseline of 7.9% (adjusted from a 
reported Japan Diabetes Society value of 7.5%). The observed 
efficacy was superior to that of the alpha-glucosidase inhibi-
tor, voglibose (−0.38%; P , 0.001), and was also associated 
with significantly better gastrointestinal tolerability.37
Three additional short-term studies have provided further 
evidence of the efficacy of vildagliptin in patients with mild 
hyperglycemia. The first 4-week study showed significant 
improvements in glycemic control with vildagliptin 100 mg 
once daily (−0.4% placebo-subtracted reduction in HbA1c; 
P , 0.001) in patients with diet-controlled diabetes and a 
mean baseline HbA1c of 7.2%.38 A second 4-week study 
reported a significant decrease in HbA1c of −0.4% relative 
to placebo from a baseline of 6.7% with vildagliptin 50 mg 
twice daily.39 In the third study,40 4 weeks of treatment with 
vildagliptin 100 mg once daily also improved glycemic con-
trol, despite a very low baseline HbA1c of approximately 6.3%, 
with a placebo-adjusted change in HbA1c of −0.3% (P = 0.002 
versus placebo). As in previous trials, vildagliptin increased 
plasma levels of intact glucagon-like peptide-1, reduced 
prandial glucose and glucagon, and increased insulin secretion 
relative to glucose, all these changes being independent of the 
patient’s severity of disease or treatment duration.
In addition to the individual studies specifically conducted 
in the patients with the lower baseline HbA1c, the efficacy 
of vildagliptin in this population was also established in 
predefined subgroup analyses of studies performed in a 
broad range of T2DM. In the pivotal study with vildagliptin 
and metformin monotherapy mentioned earlier,32 in the sub-
group of patients with baseline HbA1c #8.0%, mean HbA1c 
was reduced with vildagliptin 50 mg twice daily by −0.6% 
(n = 180) and by −0.7% with metformin (n = 79) from a 
baseline of approximately 7.6%. Similarly, in the group of 
patients with baseline HbA1c #8.0% in the 24-week study 
cited above versus rosiglitazone, a reduction of -0.6% was 
seen from a baseline of 7.7% (unpublished data). Finally, 
in a placebo-controlled dose-ranging study34 in the same 
predefined subgroup, the placebo-subtracted change in 
HbA1c with vildagliptin 50 mg twice daily was −0.7% from 
a baseline of 7.7%.
An additional interesting aspect of this latter study was 
with respect to findings for the dose response to vildagliptin 
in relation to baseline HbA1c. In the subgroup of patients 
with HbA1c #8.0%, the placebo-subtracted changes in HbA1c 
were −0.8%, −0.7%, and −0.9% with vildagliptin 50 mg once 
daily, 50 mg twice daily, and 100 mg once daily,   respectively.34 
Thus, in the lower baseline HbA1c subgroup (n = 141; mean 
baseline approximately 7.6%), the effect of vildagliptin 
was not dose-related. In contrast, in patients with baseline 
HbA1c .8.0% (n = 199; mean baseline 8.9%), 2-fold greater 
HbA1c reductions from baseline were observed with the 50 mg   
twice daily and 100 mg once daily doses versus the 50 mg 
once-daily dose regimen.34 Similar dose-response findings were 
seen in a second dose-ranging study of similar design.25 In the 
cohort of patients with baseline HbA1c .8.0% (8.8%–9.0%), 
greater efficacy was observed with vildagliptin 50 mg twice 
daily (−1.3%) or 100 mg once daily (−1.4%) than with the 
50 mg once daily dose (−0.8%). In contrast, no dose response 
was seen in the #8.0% subgroup.25 Taken together, the data 
from both these studies suggest that, at lower glycemic levels, 
a benefit of the higher daily dose regimen is not discernible, 
while at higher levels of glycemia, a 100 mg daily regimen 
appears to be more effective than the 50 mg daily regimen. 
This, together with the underlying mechanism, will be further 
discussed below.
Elderly patients
The management of T2DM in the elderly is a challenge for 
clinicians. The elderly are a very heterogeneous   population, 
in whom treatment must be individualized.24 Although treat-
ment options overall are similar to those available for younger 
patients (with metformin remaining the first choice and sulfo-
nylureas still widely used), the avoidance of hypoglycemia is 
of utmost importance in this population, because the risk of 
hypoglycemia is higher and the consequences more dramatic 
in older patients.41 In addition, the elderly are more likely to 
have multiple cardiovascular risk factors and higher rates of 
medical comorbidities, including undiagnosed renal impair-
ment and depression, as well as an increased risk of drug-drug 
interactions from polypharmacy. All of these considerations 
can limit the therapeutic choices and may reduce the degree of 
aggressiveness with which clinicians may attempt to reach and 
sustain the goals of treatment.41 However, while many older 
individuals with diabetes are on multiple antidiabetic therapies 
(with or without insulin) because of advanced disease, about 
20% of the elderly are recently diagnosed42 and thus still 
represent an appropriate population for monotherapy.
There are considerable data on the use of vildagliptin 
in elderly patients who are still good candidates for mono-
therapy and for whom insulin is neither clinically necessary 
nor practical.9
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In the 24-week head-to-head study versus metformin 
briefly mentioned earlier,33 which was conducted in T2DM 
patients with a mean age of 71 years and a mean duration 
of T2DM since diagnosis of 3 years, vildagliptin 100 mg 
once daily was as effective as metformin 1.5 g/day, a dose 
adapted to this older population, in reducing HbA1c. Adverse 
event rates were numerically lower with vildagliptin than 
with metformin (44.3% versus 50.3%) because of the   better 
gastrointestinal tolerability profile of vildagliptin, and a low 
rate of hypoglycemia was observed in both groups.33 It is also 
worth mentioning that in the 2-year study discussed earlier in 
patients with a mean HbA1c of 6.8%,30 half of the population 
was older than 65 years.
Vildagliptin monotherapy was also shown to be effec-
tive and well tolerated in treatment-naive elderly patients 
in a pooled analysis of five monotherapy trials comparing 
the effects of 24 weeks of vildagliptin treatment in younger 
(,65 years, n = 1231) and older ($65 years, n = 238) 
patients.10 Despite having lower mean baseline HbA1c and 
fasting plasma glucose, older patients had at least as good 
reductions in both measures relative to younger   individuals 
(−1.2% versus −1.0% [P = 0.092] and −1.5 mmol/L 
versus −1.1 mmol/L [P = 0.035], respectively). The rate of 
hypoglycemia was low (0.8%). Although adverse event rates 
were slightly higher in older patients compared with the 
younger population, older patients taking vildagliptin had 
lower adverse event rates (63.6%) than did older patients 
taking active comparators (68.1%). Worth noting, too, is 
the finding that vildagliptin did not increase the incidence of 
adverse events in patients with mild renal impairment (62%) 
relative to normal individuals.10
While this pooled analysis only included patients with 
mild renal impairment (estimated glomerular filtration 
rate 60–90 mL/minute/1.73 m2), the safety and efficacy of 
  vildagliptin 50 mg once daily has recently been established 
in patients with moderate (estimated glomerular filtration 
rate 30–60 mL/minute/1.73 m2) and severe (estimated 
glomerular filtration rate ,30 mL/minute/1.73 m2) renal 
impairment in a large study, which included 515 patients,43 
and is now indicated in these populations. When considering 
treating elderly patients, it is indeed important to know that 
vildagliptin can be used safely and effectively independent 
of renal function. Renal impairment is a key limitation with 
the use of many oral antidiabetic drugs and is quite common, 
though sometimes undetected, in T2DM patients. Recent 
data from a retrospective database analysis using General 
Electric medical records found that 35% of T2DM patients 
had evidence of moderate to severe renal impairment, often 
unrecognized.44 In the recent French ENTRED cohort of 
patients aged 65 years and older, this was the case for 28% of 
patients, with renal function status unknown in 13% of the 
population.42
The utility/effectiveness of vildagliptin monotherapy in 
elderly T2DM patients was further confirmed in a popula-
tion aged $75 years in a second pooled analysis (Figure 2).45 
In the monotherapy group, HbA1c decreased by −0.9%, ie, 
from a baseline of 8.3% to 7.4% at week 24 (P , 0.0001), 
a reduction similar to that reported in younger patients. There 
were no confirmed hypoglycemic events, and adverse events, 
drug-related adverse events, serious adverse events, and 
deaths were all reported at a lower frequency among patients 
receiving vildagliptin relative to comparators.
In summary, vildagliptin monotherapy could be a cred-
ible alternative for elderly T2DM patients who cannot use 
metformin, offering similar efficacy while not being limited 
by gastrointestinal tolerability or by renal impairment, which 
is frequent in this population. Vildagliptin monotherapy 
provided clinically meaningful improvement in glycemic 
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Figure 2 Change from baseline in HbA1c (A), fasting plasma glucose (B), and weight (C) with vildagliptin 50 mg twice daily in a pooled monotherapy population in patients 
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control, that was associated with an acceptably low rate of 
side effects and little risk of hypoglycemia.
Patients with prediabetes
Prediabetic conditions include impaired glucose tolerance, 
impaired fasting glucose, or both. Individuals with prediabetes 
are at high risk for development of T2DM, with 50% progress-
ing to T2DM over their lifetime.46,47 Defects in insulin action 
and β-cell function are characteristic of both impaired glucose 
tolerance and impaired fasting glucose, and progressive β-cell 
failure is the primary abnormality responsible for conversion 
of impaired glucose tolerance/impaired fasting glucose to 
overt diabetes. While lifestyle modification is the currently 
accepted treatment option for prediabetic individuals, these 
patients might one day be candidates for drug treatment, 
should treatment paradigms evolve to include individuals at 
the earliest disease stages. The release of 10-year follow-up 
data from the United Kingdom Prospective Diabetes Study48 
showed a clear legacy effect, with intensive glucose control 
introduced at the time of diagnosis being associated with a 
significantly reduced risk of myocardial infarction, all-cause 
mortality, and microvascular disease.48 These findings offer 
substantial support for a benefit of optimal glycemic control 
as early as possible in the disease process. Other than met-
formin, vildagliptin, given its mechanism of action, could 
potentially be an attractive future treatment option for these 
patients, should treatment guidelines move towards earlier 
drug treatment. In this context, it is of interest to review the 
data that have been collected on the use of vildagliptin in two 
small studies of patients with impaired glucose tolerance and 
with impaired fasting glucose.
A 12-week placebo-controlled study examined the effects 
of vildagliptin monotherapy (50 mg once daily) in individu-
als with impaired glucose tolerance (n=179).49 The results 
demonstrated that the mechanisms supporting the efficacy 
of vildagliptin in T2DM patients are operative in prediabetes 
as well. Relative to placebo, there was a marked increase in 
the postprandial GLP-1 and GIP responses with vildaglip-
tin, which was associated with improvement in both β-cell 
function (increased insulin secretion relative to glucose) and 
α-cell function (reduction of inappropriate glucagon release 
following a high carbohydrate meal), leading to decreased 
postprandial glucose levels. Twelve weeks of treatment with 
vildagliptin also led to a small but significant reduction in 
HbA1c from normal baseline levels, and patients did not 
experience any weight gain.49
In a small, uncontrolled, 6-week study in patients with 
impaired fasting glucose (n=22),50 vildagliptin 100 mg once 
daily was also shown to increase postprandial levels of intact 
GLP-1 and GIP, to increase insulin and C-peptide responses 
to intravenous glucose, and to enhance insulin sensitivity, 
while reducing glycemia.
Taken together, these two studies provide evidence 
that the known effects of vildagliptin on incretin levels 
and islet function in T2DM can be reproduced in subjects 
with impaired glucose tolerance and impaired fasting 
glucose.
Therapeutic considerations
Although different doses have been studied throughout the 
vildagliptin development program, as is also apparent from 
the current review of the different monotherapy studies, the 
two marketed doses of vildagliptin are 50 mg once daily and 
50 mg twice daily. In monotherapy, vildagliptin is approved in 
some countries as 50 mg twice daily only (eg, Japan and the 
European Union) and in other countries as both 50 mg once 
daily and 50 mg twice daily (eg, Switzerland and countries 
that refer to Switzerland for drug approval). These differences 
in approved dosing regimens represent different regulatory 
philosophies. From a risk point of view, no additional risk has 
been associated with the 50 mg twice-daily dose as opposed 
to the 50 mg once-daily dose and overall maximum efficacy 
is achieved at the twice-daily dose.25,34 On the other hand, 
it is clear from the dose-ranging studies that some patients 
do not see additional benefit of the 50 mg twice-daily dose 
compared with the 50 mg once-daily dose, and thus some 
countries label the choice of either dosage frequency. It is 
useful to examine the basis for this choice and how it might 
be applied in practice.
Vildagliptin 50 mg once daily blocks DPP-4 activity over 
the course of the three daily meals, which reduces postpran-
dial glucose during these meals. Vildagliptin 50 mg twice 
daily blocks DDP-4 activity over 24 hours, resulting in direct 
inhibition of overnight hepatic glucose production, which 
plays a more prominent role as the disease progresses.51
Most often the progression of T2DM starts with 
impaired glucose tolerance (ie, elevated postprandial 
glucose), and fasting plasma glucose can also rise second-
ary to the elevated postprandial glucose levels because 
of increased Cori cycling.52 With further progression 
of the disease, this is usually followed by much larger 
increases of fasting plasma glucose due to increas-
ing levels of   overnight hepatic glucose production. On 
average, in patients with baseline HbA1c levels #8%, 
much of the glycemic exposure is driven by elevated 
postprandial   glucose, whereas in patients with baseline 
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HbA1c levels .8%, most of the glycemic exposure is 
driven by elevated fasting plasma glucose.53 However, 
while this is generally true in populations, in individuals 
an HbA1c of 7%–8% may still be associated with a fasting 
plasma glucose of 7 mM, which is not associated with an 
important rise in overnight hepatic glucose production, 
or with a fasting plasma glucose of up to 10 mM, which 
is associated with an important rise in overnight hepatic 
glucose   production.51 In addition, in a clinical setting, 
fasting plasma glucose is quite variable. These consid-
erations make it difficult to determine which individual 
patients experience glycemia that is not primarily driven 
by overnight hepatic glucose production.
Thus, while in patients with a baseline HbA1c #8.0% in 
study populations there was on average no efficacy benefit 
associated with the twice-daily versus once-daily vildaglip-
tin dose, as discussed earlier, using either HbA1c or fasting 
plasma glucose as a basis for using a once-daily dose in 
individuals may result in some patients receiving a subopti-
mal dose. In the absence of any safety or tolerability issues 
associated with the twice-daily dose versus the once-daily 
dose, the European and Japanese labels recommend twice-
daily dosing for vildagliptin monotherapy in all patients.
It is worth mentioning the following further consideration 
related to dosing. In addition to the pancreatic effect of reducing 
glycemia, vildagliptin has an extrapancreatic effect of reducing 
fasting lipolysis treatment.54 Over weeks, reduced fasting lipoly-
sis leads to reduced levels of stored triglycerides in nonfat tis-
sues (muscle and liver), as shown by increased insulin-mediated 
glucose disposal at the expense of lipid oxidation (ie, reduced 
lipotoxicity) observed after 6 weeks of vildagliptin 50 mg twice 
daily treatment.54 Because fasting lipolysis occurs during the 
overnight postabsorptive period, this effect requires twice-daily 
dosing to cover the overnight period. The additional benefit 
of reduced lipotoxicity with vildagliptin may be an important 
contributor to an improved metabolic state.
Taken together, in most patients with normal or mildly 
impaired renal function, vildagliptin 50 mg twice daily is the 
appropriate dose for monotherapy. Of note, in patients with 
moderate or severe renal impairment, vildagliptin 50 mg 
once daily blocks DPP-4 activity over 24 hours (reflecting 
the increased exposure) and thus 50 mg once daily is the 
appropriate dose.43
Conclusion
Vildagliptin has been shown to be a well tolerated and 
efficacious monotherapy for patients with T2DM. The 
ability of vildagliptin to improve glucose tolerance also 
extends into the impaired glucose tolerance and impaired 
fasting glucose populations. When metformin is not 
appropriate, vildagliptin has hypoglycemic and weight 
benefits relative to sulfonylureas, particularly appreciable 
in patients with lower baseline HbA1c levels and in the 
elderly population.
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